“We are a responsibly-driven company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.”
The Seelos Way
- Assets must serve a large unmet medical need, orphan population or a unique approach to existing treatments
- Assets must possess extensive scientific rationale and/or existing human data
- Seelos will look for clinically ready assets or assets where minimal pre-clinical work will be needed
- The clinical development pathway should make economic sense and be appropriate for a company our size
Please review our Privacy Policy, Terms of Use, and Accessibility information located at the bottom of this page.